Unexploded ordnance clearance operations with saturation divers MILAN, Italy, Aug. 01, 2023 (GLOBE NEWSWIRE) — At the construction site of the new breakwater dam in Genoa, underwater unexploded ordnance clearance operations have begun at depths of up to 50 meters. Webuild, the first company in Italy to do so, is

An agreement has been signed between the two companies to manage environmental remediation projects at several industrial sites MILAN, Italy, Aug. 01, 2023 (GLOBE NEWSWIRE) — Eni and Edison have reached an agreement that marks the collaboration between the two companies for the management of environmental remediation projects at all

Innovative solution leverages automated A/B testing technology to optimize airlines’ ancillaries aiming at total net revenue maximization SANTIAGO, Chile, Aug. 01, 2023 (GLOBE NEWSWIRE) — Airnguru, a cloud-native provider helping airlines optimize their pricing strategies, has announced the launch of a dynamic pricing engine for bundle discounts that enables airlines

Ignitis Group’s subsidiary, Ignitis Renewables and Copenhagen Infrastructure Partners (CIP), through its New Markets Fund, have signed an agreement to collaborate exclusively on offshore wind opportunities in Estonia and Latvia. The partnership leverages Ignitis Group’s leading market position in the Baltic region and CIP’s global offshore wind expertise. COPENHAGEN, Denmark

Report from Enterprise Strategy Group reveals that the integrated Fortinet SecOps Fabric automatically contains incidents in minutes or even seconds SUNNYVALE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) — John Maddison, Chief Marketing Officer and EVP, Product Strategy “To secure the rapidly expanding attack surface against accelerating cyberthreats, enterprises must deploy

Study found obexelimab produced rapid, strong, and sustained clinical improvement, including complete clinical remission, in most patients with active IgG4-RD Results support the continued development of obexelimab for the treatment of IgG4-RD and potentially other B cell-mediated autoimmune conditions WALTHAM, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) — Zenas BioPharma, a